MULTICENTER EVALUATION OF THE INVITRO ACTIVITIES OF 3 NEW QUINOLONES, SPARFLOXACIN, CI-960, AND PD-131,628, COMPARED WITH THE ACTIVITY OF CIPROFLOXACIN AGAINST 5,252 CLINICAL BACTERIAL ISOLATES

The in vitro activities of three new quinolones (sparfloxacin, CI-960, and PD 131,628) were compared with that of ciprofloxacin against 5,252 routine clinical aerobic and facultatively anaerobic bacterial isolates. Overall, CI-960 was the most active drug in vitro (MIC for 90% of the strains tested, 1.0-mu-g/ml). All three new quinolones, and sparfloxacin were the least active (MIC for 90% of the strains tested, 0.13-mu-g/ml); ciprofloxacin and sparfloxacin were the least active (MIC for 90% of the strains tested, 1.0-mu-g/ml). All three new quinolones, but particularly CI-960 and PD 131,628, exhibited significantly greater activity than ciprofloxacin against enterococci and staphylococci.